Check Cap (CHEK) Stock Rating Upgraded by Zacks Investment Research

Check Cap (NASDAQ:CHEK) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Friday, Zacks.com reports.

According to Zacks, “Check Cap Ltd. is a medical diagnostics company. The company is engaged in the development of an ingestible imaging capsule for the screening of colorectal cancer. Check Cap Ltd. is based in Mount Carmel, Israel. “

Separately, Dougherty & Co began coverage on shares of Check Cap in a research note on Tuesday, February 5th. They issued a “buy” rating and a $6.00 price target on the stock.

Shares of Check Cap stock opened at $2.67 on Friday. The stock has a market cap of $4.27 million and a price-to-earnings ratio of -1.02. Check Cap has a 12-month low of $1.62 and a 12-month high of $5.20.

Check Cap (NASDAQ:CHEK) last announced its quarterly earnings data on Monday, May 13th. The medical research company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.03. Equities analysts predict that Check Cap will post -1.69 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Jane Street Group LLC acquired a new stake in shares of Check Cap in the 1st quarter valued at approximately $89,000. Renaissance Technologies LLC boosted its stake in shares of Check Cap by 101.4% in the 1st quarter. Renaissance Technologies LLC now owns 247,442 shares of the medical research company’s stock valued at $668,000 after purchasing an additional 124,600 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Check Cap by 16.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 40,773 shares of the medical research company’s stock valued at $110,000 after purchasing an additional 5,642 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its stake in shares of Check Cap by 96.0% in the 1st quarter. Wells Fargo & Company MN now owns 9,800 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 4,800 shares in the last quarter.

Check Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.

Featured Story: What is a support level?

Get a free copy of the Zacks research report on Check Cap (CHEK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.